Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy

A year after dolling out $11.5 billion to buy Acceleron Pharma, Merck is experiencing the first taste of potential from one of the drugs it acquired in the process—and it’s sweet.